Drug Database
CO

controlled release tech

✓ Approved

Relief Therapeutics Holding AG · therapeutic agent

What is controlled release tech?

controlled release tech is a therapeutic agent developed by Relief Therapeutics Holding AG. It is approved for therapeutic indications via oral (po).

Drug Profile

CompanyRelief Therapeutics Holding AG
RouteOral (PO)
StatusApproved

Therapeutic Indications

controlled release tech is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Surgical and medical proceduresOral appliance application✓ Approved

Related Research Articles

PubMedThe South African journal of psychiatry : SAJP : the journal of the Society of Psychiatrists of South Africa2026-11-11

Prevalence and determinants of readmission at a tertiary psychiatric hospital in Zanzibar.

Abdallah Abdallah K AK, Ottaru Theresia A TA, Moshiro Candida C

Psychiatric readmission is a global concern, leading to poorer clinical outcomes and higher healthcare costs. In Tanzania, where mental health services operate within a resource-constrained health system, repeated psychiatric admissions may place additional pressure on already limited services. However, local evidence on psychiatric readmission remains limited. To determine the prevalence of psychiatric readmission and its determinants among psychiatric patients admitted to a tertiary psychiatric hospital in Unguja, Zanzibar. A tertiary psychiatric referral hospital in Unguja, Zanzibar, serving patients across Unguja and Pemba islands. A cross-sectional study was conducted among psychiatric patients 18 years and older admitted between June 2024 and August 2024. Data were collected through interviewer-administered questionnaires. Modified Poisson regression with robust error variance was used to identify factors associated with psychiatric readmission. A total of 311 patients (mean age 36, standard deviation [s.d.] = 11 years; females 52.4%; schizophrenia 32.5%) were enrolled. The prevalence of psychiatric readmission within 3 months was 58.5% (n = 182). Readmission was associated with age group 30-39 years (adjusted prevalence ratio [APR] = 1.47; 95% confidence interval [CI]: 1.16-1.84, p-value [p] = 0.001), schizophrenia (APR = 1.23; CI: 1.00-1.50, p = 0.041), bipolar disorders (APR = 1.69; CI: 1.26-2.26, p < 0.001), higher education (APR = 1.61; CI: 1.16-2.22, p = 0.010), history of physical abuse (APR = 1.49; CI: 1.16-2.22, p < 0.001), and being prescribed both oral and injectable medications (APR = 1.46; CI: 1.37-2.20, p < 0.001). There is a high psychiatric readmission rate in Zanzibar. Interventions should focus on high-risk groups, particularly middle-aged individuals and those requiring combination treatment to break the cycle of readmission and promote long-term mental health recovery. This study provides evidence on psychiatric readmission in Zanzibar and identifies high-risk groups requiring targeted post-discharge intervention in low-resource psychiatric settings.

PubMedBMC public health2026-11-11

Acceptability of the RTS, S malaria vaccine and associated factors among caregivers‌ of children⁠ under 25 months‍ in Soa⁠ Health District, Cameroon: a community-based cross-sectional st⁠udy‍.

Dang Ludrique L, Ombogo Fabien Fouda FF, Burinyuy Bime Brenda BB, Kamdem Gilles Tounsi GT et al.

Malaria remains a major cause of morbidity an‌d mortality in sub-Saharan Afri‌ca. I‌n C‌ameroon, malaria accounts for 48% of all hospital admissions, 30% of morbidity, and 67% of childhood mortality per year. Despite the introduction of RTS, S in‍ several African countries, real-world evidence on community acceptability following vaccine rollout remains limited, particularly at the district level. Understanding caregivers' willingness to vaccinate is critical for optimizing uptake and‌ guiding context-specific implementation strategies. A community-‍bas‌ed cross-sectional st⁠ud‌y was conducted between March and November 2024 in th‌e S⁠oa Hea‍lth District (HD).‍ A total of 5‍41 caregi⁠vers of children unde‍r‍ 25 mon‍ths w‌ere‍ recruited using a non-pro‌b‌ability con‍venience sam⁠pling method. Data were collected using a s‍tr‍uctured pre-tested q⁠uestionnaire and analysed using R s‍oftware. Modified Poisson reg‍ression mod‍els with robust variance esti‍mation was used to obtain crude and adjuste‍d prev⁠alence‌ ratio (CPR and APR) with‍ 9⁠5% conf‍idence interval⁠s (95% CI‍s), a statistical significance was set at p-value < 0.05. Among the 541 caregi⁠vers, 73.4% expressed willingness to v‌accinate their children against malari‍a. Higher vaccine acceptability was independently associated with residing in Kou‌lou (AP⁠R =⁠ 1.4; 95% CI: 1.1-2.0), Ngali 2 (⁠APR = 1⁠0.6; 95% CI: 1.‍2-2.2), and So⁠a‌ (APR = 1.6; 95‍% CI‍: 1.1-2.2) compared with Nts‍ouesso⁠ng; female sex (APR = 1.2; 95% CI: 1‍.‌0-‌1.3); origine from the North-West, Sou‍th-W‍est‍, West, and Littoral regions (A⁠PR = 1.2; 95% CI: 1.‌1‍-‌1.4); use‍ s‍tr‌eet medicine (APR = 1.3; 95% CI: 1.0-1.6) or prescribed medicin‌e (APR = 1⁠0.2; 95% CI: 1⁠0.0-1.5) rather than tra‍d‍it⁠ional med‍i‍cine‍ for malaria treatment; pr⁠ior awareness of the malaria vac‍cine (APR = 1.2‍; 95%‌ CI: 1.1-1.4)⁠. All p < 0.05. CONCLUSI‍ON: Acce⁠ptabi‌lity of the malaria va‌ccine among caregivers in the Soa HD was relativel‍y high and was significantly influenced by geographic location, sex,‍ region, health-seeking behaviour, and awareness of the⁠ vaccine.‌ Targeted health e‌duc‍ati‍on and cul‌turally sensitive community engagement strategies‍ are‍ essential to improve vac⁠cine acceptability and su⁠pp⁠ort‌ the successf‌u‍l s‍cale‍-up of⁠ ma‍lari‌a vaccination programmes in Cameroon and other endemic se‌ttings. Not applicable.

PubMedNature biotechnology2026-11-11

Are AI tech giants hijacking drug discovery?

De Francesco Laura L

PubMedBiomaterials science2026-11-11

Correction: Tailoring the biological performance of titanium implants via a TaCu nanocoating on MAO-porous layers: the interplay between surface topography and controlled Cu2+ release.

Yao Litao L, Tong Yuanhao Y, Lin Xiaohong X, Huang Mengmeng M et al.

Correction for 'Tailoring the biological performance of titanium implants via a TaCu nanocoating on MAO-porous layers: the interplay between surface topography and controlled Cu2+ release' by Litao Yao et al., Biomater. Sci., 2026, https://doi.org/10.1039/d6bm00600k.

PubMedJournal of racial and ethnic health disparities2026-11-11

Healthcare Discrimination and Psychological Distress in a Multi-State Sample of U.S. Adults.

Binns Ariel Adelaide AA, Huang Madalyn M, Choe Karen K, Cuevas Adolfo G AG et al.

This study examined the association between perceived healthcare discrimination and psychological distress in a multi-state sample of U.S. adults. Data were drawn from 3847 adults (mean age = 49.33 years, 50.8% non-Hispanic White) from the 2023 Survey of Racism and Public Health. Psychological distress was measured using the Kessler Psychological Distress Scale. Healthcare discrimination was self-reported. Covariates included demographic characteristics, socioeconomic status, self-rated health, and health literacy. Modified Poisson regression estimated adjusted prevalence ratios (aPR) with 95% CIs. Participants who experienced healthcare discrimination had a 44% higher prevalence of high psychological distress than those who did not (aPR = 1.44; 95% CI: 1.19, 1.75). There was no empirical evidence that this association was moderated by race/ethnicity. Perceived healthcare discrimination may represent a critical determinant of psychological distress, and this association appears consistent and invariable across racial and ethnic lines.

PubMedCell reports. Physical science2026-11-11

Ultrasound-activated drug release with extracellular vesicles.

Shi Xi X, He Weilong W, Xu Haiyue H, Dasgupta Rinki R et al.

Precise, noninvasive targeting and controlled drug release to the nervous system can transform both basic research and clinical therapy. Ultrasound combined with artificial carriers offers a promising approach for precise, noninvasive drug release. Here, we report a focused ultrasound (FUS)-responsive delivery system based on extracellular vesicles (EVs), which are naturally occurring, biocompatible phospholipid nanocarriers. To enable ultrasound responsiveness, the lipid-gas phase-transition material perfluoropentane (PFP) is co-encapsulated with therapeutic agents into EVs via low-temperature sonication. The resulting EVs are 100-200 nm in size and demonstrate efficient, on-demand release upon ultrasound stimulation. In primary cultured neurons, FUS-triggered release from EVs loaded with PFP and lidocaine suppresses neuronal activity with minimal cytotoxicity. We further demonstrate in vivo modulation of pain sensitivity in rats. Overall, this EV-based platform enables safe, ultrasound-activated drug delivery and supports therapeutic applications of lipid nanocarriers.

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about controlled release tech